C71
Conditions
Interventions
Group 1: Study participants will receive additional PET scans as part of the study: at the time of initial diagnosis, patients will receive a preoperative TSPO-PET (FET-PET as part of clinical routine
Sponsors
Klinik und Poliklinik für Nuklearmedizin, LMU Klinikum der Universität München
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Suspected newly diagnosed glioma CNS-WHO Grade 2-4; signed informed consent; age = 18 years.
Exclusion criteria
Exclusion criteria: Patients who are not eligible for tumor-specific therapy (radiation, chemotherapy, or radiochemotherapy depending on tumor type); patients who are unable to give informed consent due to an accompanying psychiatric disorder; known history of alcohol or drug abuse in the 12 months prior to screening; contraindications for magnetic resonance imaging (pacemaker or implanted metal in the skull) or PET imaging; pregnancy / breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation of the TSPO-PET signal and FET-PET signal with tissue samples at initial diagnosis and in recurrence using immunohistochemistry, cell separation, and flow cytometry, as well as correlation of molecular changes within heterogeneous tumor areas (exploratory) | — |
Secondary
| Measure | Time frame |
|---|---|
| Longitudinal detection of changes in the TSPO signal using TSPO-PET and correlation of image signal differences with treatment response (according to PET RANO 1.0) as well as the timing and location of recurrence (exploratory) | — |
Countries
Germany
Contacts
Public ContactNathalie Albert
Klinik und Poliklinik für Nuklearmedizin, LMU Klinikum der Universität München Marchioninistraße 15 81377 München Deutschland
Outcome results
None listed